The Effects of N-acetylcysteine on Inflammatory Markers and Homocysteine: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Jamal Hallajzadeh1, Alireza Milajerdi2, Željko Reiner3, Fariba Kolahdooz4, Zatollah Asemi5*

1Department of Biochemistry and Nutrition, Research Center for Evidence-Based Health Management, Maragheh University of Medical Sciences, Maragheh, Iran.
2Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.
3Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.
4Department of Internal Medicine, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia.
5Indigenous and Global Health Research, Department of Medicine, University of Alberta, Edmonton, Canada.
6Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran.

Article Info
Article History:
Received: 15 December 2019
Accepted: 9 April 2020
ePublished: 20 September 2020

Keywords:
- N-acetylcysteine
- Inflammatory markers
- Interleukin-6
- Tumor necrosis factor α
- Homocysteine
- Meta-analysis

Abstract
Background: Recently a number of trials investigated the effect of N-acetylcysteine (NAC) administration on inflammatory markers and homocysteine (Hcy). However, their findings are controversial. The aim of this paper is to present a meta-analysis and give a review of all randomized controlled trials (RCTs) in order to determine the effects of NAC on inflammatory markers and Hcy.

Methods: An electronic search was conducted using PubMed, Scopus, Cochrane Library, Google scholar and Web of Science databases from inception until April 2019. A study quality assessment was performed using the Jadad scale and heterogeneity between studies was statistically computed using Cochrane's Q test and I-square (I2). Data were pooled using a random-effects model and weighted mean difference (WMD) was considered as the overall effect size.

Results: Out of 1115 potential citations, 10 studies (reported 13 effect sizes for different parameters) met the inclusion criteria and were eligible for this meta-analysis. NAC supplementation resulted in a significant reduction in Hcy levels (WMD: -2.05; 95% CI: -3.73, -0.37). NAC administration did not affect C-reactive protein (CRP) levels (WMD: 0.06; 95% CI: -0.21, 0.34), tumor necrosis factor-α (TNF-α) levels (WMD: 0.07; 95% CI: -0.27, 0.40), and interleukin 6 (IL-6) (WMD: -0.23; 95% CI: -1.23, 0.77).

Conclusion: It could be concluded that this meta-analysis of RCTs demonstrated that NAC administration to various patients significantly improved circulating Hcy, but did not affect CRP IL-6 and TNF-α levels.

Introduction
N-acetylcysteine (NAC) is a sulfhydryl group (SH) compound with the chemical formula C5H9NO3S and is precursor, i.e. the acetylated form of L-cysteine. Acetyl group in this molecule protects it from oxidation. The acetylation, also, facilities reduced polarity and tissue uptake. NAC has been reported to play a role in a wide range of disorders, including HIV infection, cancer, chelation in metal toxicity, acetaminophen poisoning, Sjögren's syndrome, psychiatric disorders, sepsis, influenza, inflammatory bowel disease and cardiovascular disease (CVD). NAC has its therapeutic application due to its direct and indirect antioxidant and anti-inflammatory activity. Direct antioxidant effect of NAC occurs because of reaction with free radicals and interaction with reactive oxygen species (ROS), precisely with its free thiol group. The indirect antioxidant function of NAC is related to its role as glutathione (GSH) precursor, resulting in increase of intracellular GSH concentration, particularly in liver cells where it is an important intracellular antioxidant. Namely NAC acts mainly as the supply of cysteine for GSH synthesis.

A plethora of studies have demonstrated anti-inflammatory effects of NAC. This activity is related to suppression of nuclear factor-κB (NF-κB) activity. Coupling IκB to NF-κB prevents from translocation of NF-κB to nucleus. IκB with phosphorylation of IκB and dissociation of

*Corresponding Author: Zatollah Asemi. E-mail: asemi_r@yahoo.com
©2020 The Author(s). This is an open access article and applies the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited.
IxKβ facilitates degradation of IxKβ by the proteasome, nuclear translocation of NF-xKβ and transcription of genes involved in inflammation such as interleukin-1β (IL-1β), IL-6, IL-8, and tumor necrosis factor-α (TNF-α).15 NAC suppresses the activation of IKKβ/NF-κB axis by two ways. First, NAC directly inhibits the 26s proteasome activity.16 Secondly, NAC scavenges ROS by thiol group or indirectly by increasing synthesis of reduced GSH that causes suppression of IKKβ.17 Homocysteine (Hcy) is a sulfhydryl group containing amino acid related to methionine metabolism. Hcy can be have various fate in the body. Hcy may be converted to methionine by folic acid, B12 and betaine-dependent remethylation pathways or can be converted, via the trans-sulfuration pathway, into cysteine.18 Hyperhomocysteinemia is considered as a risk factor for CVD and stroke since Hcy is known to have adverse effects on vascular endothelium and smooth muscle cells with resultant alterations in subclinical arterial structure and function. High-dose folic acid, vitamin B6 or B12, serine, or betaine cannot normalize hyperhomocysteinaemia in the individuals that are resistant to conventional treatment.19,20 Nevertheless, it has been shown that administration of NAC orally or intravenously dramatically decreases Hcy levels.21-23

However, the effects of NAC on circulating inflammatory markers and Hcy are controversial and no studies have been done to analyze the effects of NAC on both inflammatory biomarkers and Hcy. Therefore, the aim of this study was to perform a meta-analysis and summarize systematically the present evidence from RCTs concerning the effects of NAC on inflammatory markers and Hcy levels in various diseases.

Methods
Search strategy
Two authors independently searched electronic databases including PubMed, Scopus, Cochrane Library, Google scholar and Web of Science databases from inception up to April 2019 for relevant RCTs investigating the associations between NAC administration and inflammatory markers and Hcy. The search strategy was limited to RCTs in humans and published in English. The following MeSH and text keywords were used to identify primary RCTs: intervention (“N-acetylcysteine” OR “NAC”), and parameters “[C-reactive protein (CRP)” OR “tumor necrosis factor-α (TNF-α)” OR “interleukin 6 (IL-6)” OR “homocysteine (Hcy)”. The reference lists of related RCTs and previous reviews were manually searched to detect further studies which were not captured in our primary search.

Inclusion and exclusion criteria
RCTs with the following criteria were included in meta-analysis: human trials with either parallel or cross-over design, data on the effects of NAC on inflammatory markers and Hcy extracted from RCTs with standard deviation (SD) and related 95% confidence intervals (CIs) for both intervention and placebo groups. Other studies such as animal experiments, in vitro studies, case reports, observational studies, investigations without control group, trials with ≤ 2 weeks period and studies that did not achieve the least quality score were excluded.

Data extraction and quality assessment
Two independent authors (JH and AM) screened the retrieved articles based on the eligibility criteria. As the first step the title and abstract of studies were reviewed. Then, the full-text of relevant studies was analyzed to ascertain the suitability of a study for the meta-analysis. Any disagreement was resolved through the judgment of the third author (ZA).

The following data extracted from the selected studies: the first authors’ name, year of publication, study location, sample size, study design, dosage of supplementation, duration of the intervention, type of disease, the mean and SD for inflammatory markers and Hcy in each intervention group. The same two authors assessed the studies’ quality independently using the Jadad scale.

Data synthesis and statistical analysis
The pooled effects of NAC supplementation on inflammatory markers and Hcy were calculated using change score approach. Weighted mean difference (WMD) with 95% CI was used for pooling data to determine the pooled effect sizes by utilizing the random-effect model.

Heterogeneity and publication bias
Heterogeneity across included studies was evaluated using Cochrane’s Q test (with significant P-value <0.1) and I-square test (12 greater than 50 percent showing significant heterogeneity). The funnel plot, as well as the Beggs’s and Egger’s regression tests was used to determine the publication bias. Both STATA 11.0 (Stata Corp., College Station, TX) and Review Manager 5.3 (Cochrane Collaboration, Oxford, UK) were applied for data analysis.

Assessment of study quality was conducted using the Jadad scale.

Results
Characteristics of the included studies
General characteristics of included studies are presented in Table I. Ten studies which reported 13 effect sizes were included. Flowchart of study selection procedure is shown in Figure 1. These studies were published between 2003 and 2019. A total of 587 participants, including 340 individuals in the intervention and 247 persons in the control groups, were enrolled in these trials. The studies were conducted in Iran, Turkey, Poland, Australia, Italy, Island and Spain. Included trials were done among healthy participants, workers with lead exposure, depressive patients, patients with T2DM, dialysis subjects and patients with ulcerative colitis. Duration of intervention was varied from 1 to 6 months and the dosage of NAC supplements was varied between 200 mg/d to 2400 mg/d. In four studies, NAC
A Comprehensive Review on Developed Pharmaceutical Analysis Methods by Iranian Analysts in 2018

Table 1. Characteristics of included studies.

| Authors (Ref) | Publication year | Sample size (control/intervention) | Type of study | Country | Health status | Intervention (name and daily dose) | Duration | Age (y) (control, intervention) | Presented data (placebo) | Presented data (intervention) |
|---------------|-----------------|----------------------------------|--------------|---------|--------------|-----------------------------------|----------|-------------------------------|--------------------------|--------------------------|
| Panizzutti et al.\(^a\)\(^b\) | 2018 | 15/13 | Placebo-controlled randomised trial | Australia | Bipolar depression received 2000 mg/d NAC in past 2 months | 2000 mg/d NAC + usual treatment | 6 months | 22-70 | TNF-α↓ | TNF-α↑ |
| Vural et al.\(^c\) | 2018 | 17/23 | Prospective, randomized, controlled, and open label study | Turkey | Peritoneal dialysis | 1200 mg/d NAC | 1 month | 49±13, 46±15 | IL-6↑, TNF-α↑ | IL-6↓, TNF-α↓ |
| Martina et al.\(^d\) | 2008 | 12/12 | Randomized, double-blind, placebo-controlled study | Italy | Male patients with T2DM and HTN | 1200 mg/d NAC + 1200 mg/d L-arginine | 6 months | 67±16.5, 62.5±13.4 | CRP↔, IL-6↔, TNF-α↓, Hcy↓ | CRP↓, IL-6↑, TNF-α↑, Hcy↑ |
| Guijarro et al.\(^e\) | 2008 | 18/19 | Randomized, placebo-controlled pilot study | Spain | Ulcerative colitis | 800 mg/d NAC + mesalamine | 4 weeks | 42.2± 13, 51.4± 14 | IL-6↓, TNF-α↑ | IL-6↓, TNF-α↑ |
| Hasebe et al.\(^f\) | 2017 | 63/58 | Prospective, randomized, double-blind, placebo-controlled study | Australia | Unipolar depression | 2000 mg/d NAC + usual treatment | 12 weeks | 20-77 | CRP↓, IL-6↓ | CRP↓, IL-6↑ |
| Bashardoust et al.\(^g\) | 2018 | 25/26 | Randomized placebo-controlled clinical trial | Iran | Hemodialysis patients | 1200 mg/d NAC | 1 month | 62.76±14.47, 65.50±11.05 | CRP↓ | CRP↓ |
| Abasi Larki et al.\(^h\) | 2019 | 19/21 | Double-blind, randomized clinical trial | Iran | Hemodialysis patients | 1200 mg/d NAC | 8 weeks | 61.05±19.09, 60.61±16.61 | CRP↓, IL-6↓ | CRP↓, IL-6↓ |
| Friedman et al.\(^i\) | 2003 | 16/18 | Randomized placebo-controlled trial | Island | Hemodialysis | 2400 mg/d NAC | 4 weeks | 70±4, 68±3 | Hcy↓ | Hcy↓ |
| Ventura et al.\(^j\) (a) | 2003 | 6/14 | Not reported | Italy | Healthy subjects | 600 mg/d NAC | 1 month | 44±19, 42±11 | Hcy↑ | Hcy↓ |
| Ventura et al.\(^j\) (b) | 2003 | 7/14 | Not reported | Italy | Healthy subjects | 1800 mg/d NAC | 1 month | 44±19, 46±14 | Hcy↑ | Hcy↓ |
| Kasperczyk et al.\(^k\) (a) | 2016 | 16/40 | Not reported | Poland | Lead-exposed workers | 200 mg/d NAC | 12 weeks | 42.5±8.66 | Hcy↓ | Hcy↔ |
| Kasperczyk et al.\(^k\) (b) | 2016 | 17/44 | Not reported | Poland | Lead-exposed workers | 400 mg/d NAC | 12 weeks | 42.5±8.66 | Hcy↓ | Hcy↓ |
| Kasperczyk et al.\(^k\) (c) | 2016 | 16/38 | Not reported | Poland | lead-exposed workers | 800 mg/d NAC | 12 weeks | 42.5±8.66 | Hcy↓ | Hcy↓ |

CRP; C-reactive protein; IL-6; interleukin-6; TNF-α; tumor necrosis factor-α
N-acetylcysteine intake and inflammation and homocysteine

was used at a daily dosage of 1200 mg. In some studies, NAC consumption was along with usual treatment or the administration of other compounds like mesalamine or L-arginine. Measured outcomes were: CRP (4 studies), IL-6 (5 studies), TNF-α (4 studies) and Hcy (4 studies, 7 effect size).

The effects of NAC on inflammatory cytokines
Analysis of 4 studies did not show any significant effect on CRP concentrations following NAC supplementation (WMD: 0.06; 95% CI: -0.21, 0.34) (Figure 2A and Table 2). This finding remained unchanged after subgroup analysis by the study sample size (Table 3).

Analysis of 4 studies showed no significant changes in TNF-α levels (WMD: 0.07; 95% CI: -0.27, 0.40) following NAC supplementation (Figure 2B and Table 2). Subgroup analyses by the study location and study duration showed no significant effects of NAC supplementation on serum TNF-α concentrations, however, we found a significant elevation of TNF-α levels in studies done in European countries (WMD: 0.14; 95% CI: 0.11, 0.17) and those with a duration of < 8 weeks (WMD: 0.14; 95% CI: 0.11, 0.17) (Table 3).

NAC administration did not significantly change IL-6 levels, as shown in the meta-analysis of 5 studies (WMD: -0.23; 95% CI: -1.23, 0.77) (Figure 2C and Table 2). In the subgroup analyses, a significant reduction of IL-6 levels was seen among studies done in European countries, studies with a duration of <8 weeks, and those done in subjects aged <60 years (for all: WMD: -0.22; 95% CI: -0.26, -0.18) (Table 3).

The effects of NAC on homocysteine
Pooling findings of 7 effect sizes showed a significant reduction in Hcy levels following NAC supplementation (WMD: -2.05; 95% CI: -3.73, -0.37) (Figure 2D and Table 2). This finding did not change after subgroup analysis by the study duration and dosage (Table 3).

Findings from dose-response analysis about NAC intake on inflammatory markers and Hcy revealed that the overall pooled estimates on inflammatory markers and Hcy were independent of NAC dosage. We failed to detect a significant effect of specific dosage of NAC on inflammatory markers and Hcy, as examined by non-linear dose-response meta-analysis (Figure 3A-D).

Regarding the study quality, presented in Table 4, four publications had a Jadad score of 2 (Vural et al, Panizzutti et al, Ventura et al and Kasperczyk et al) and others had a score of ≥3.
Figure 2. Meta-analysis on outcome standardized mean differences estimates for CRP in N-acetylcysteine and placebo groups (CI=95%).
N-acetylcysteine Intake and Inflammation and Homocysteine

Table 2. The effects of N-acetylcysteine on inflammatory markers and homocysteine.

| Variables     | Number of effect sizes | Weighted Mean difference | CI 95%            | Heterogeneity | P-value heterogeneity |
|---------------|------------------------|--------------------------|-------------------|---------------|----------------------|
| CRP           | 4                      | 0.06                     | -0.21, 0.34       | 18.5          | 0.29                 |
| IL-6          | 5                      | -0.23                    | -1.23, 0.77       | 61.1          | 0.03                 |
| TNF-α         | 4                      | 0.07                     | -0.27, 0.40       | 57.2          | 0.07                 |
| Homocysteine  | 7                      | -2.05                    | -3.73, -0.37      | 75.8          | <0.001               |

CRP: C-reactive protein; IL-6: interleukin-6; TNF-α: tumor necrosis factor-α

Table 3. Subgroup analyses for the effects of N-acetylcysteine on inflammatory markers and homocysteine.

| Variables     | Subgroups               | Number of effect sizes | Pooled WMD | 95% CI          | I² (%) | P-value heterogeneity |
|---------------|-------------------------|------------------------|------------|-----------------|--------|-----------------------|
| CRP           | Study sample size       | <50                    | 2          | -0.02           | -0.06, 0.03 | 68.5 | 0.54 |
|               |                         | ≥50                    | 2          | -0.57           | -2.32, 1.19 | 00.0 | 0.0     |
| IL-6          | Study location          | European countries     | 2          | -0.22           | -0.26, -0.18 | 26.7 | 0.96 |
|               |                         | Non-European countries | 3          | -0.20           | -1.14, 0.74 | 77.5 | 0.0     |
|               | Study duration          | <8 weeks               | 2          | -0.22           | -0.26, -0.18 | 88.1 | 0.23 |
|               |                         | ≥8 weeks               | 3          | 0.29            | -0.56, 1.15 | 00.0 | 0.0     |
|               | Participants’ age        | <60 years              | 3          | -0.22           | -0.26, -0.18 | 77.6 | 0.25 |
|               |                         | ≥60 years              | 2          | 0.85            | -0.99, 2.69 | 00.0 | 0.0     |
| TNF-α         | Study location          | European countries     | 2          | 0.14            | 0.11, 0.17 | 00.0 | 0.40 |
|               |                         | Non-European countries | 2          | 0.01            | -0.31, 0.32 | 84.1 | 0.0     |
|               | Study duration          | <8 weeks               | 2          | 0.14            | 0.11, 0.17 | 84.9 | 0.0     |
|               |                         | ≥8 weeks               | 2          | 0.05            | -0.27, 0.36 | 84.1 | 0.0     |
| Homocysteine  | Study duration          | <8 weeks               | 3          | -2.04           | -3.43, -0.64 | 00.0 | 0.34 |
|               |                         | ≥8 weeks               | 4          | -1.25           | -2.09, -0.41 | 86.8 | 0.40 |
|               | Participants’ age        | <60 years              | 5          | -1.49           | -2.26, -0.71 | 83.6 | 0.0     |
|               |                         | ≥60 years              | 2          | -1.32           | -3.27, 0.63 | 86.6 | 0.43 |
|               | Supplementation dosage  | <1000 mg/d             | 4          | -1.31           | -2.13, -0.50 | 86.6 | 0.43 |
|               |                         | ≥1000 mg/d             | 3          | -2.02           | -3.59, -0.45 | 86.6 | 0.43 |

CRP: C-reactive protein; IL-6: interleukin-6; TNF-α: tumor necrosis factor-α.

A: CRP, p=0.67
Figure 3. Non-linear dose-response relations between NAC dosage and inflammatory markers and Hcy in (A) CRP, (B) IL-6, (C) TNF-α and (D) Hcy levels. The 95% CI is demonstrated in the shaded regions.
**Table 4. Methodological quality scores for included studies using Jadad scale.**

| Authors (Year) | Randomization | Blinding | Account of all patients | Total Score |
|----------------|---------------|----------|-------------------------|-------------|
| Panizzuti et al.24 2018 | 1 | 1 | 0 | 2 |
| Vural et al.25 2018 | 1 | 0 | 1 | 2 |
| Martina et al.26 2008 | 1 | 2 | 1 | 4 |
| Guijarro et al.27 2008 | 2 | 0 | 1 | 3 |
| Hasebe et al.28 2017 | 1 | 1 | 1 | 3 |
| Bashardoust et al.29 2018 | 2 | 2 | 1 | 5 |
| Abasi Larki et al.30 2019 | 2 | 2 | 1 | 5 |
| Friedman et al.31 2003 | 1 | 2 | 1 | 4 |
| Ventura et al.32 2003 | 1 | 0 | 1 | 2 |
| Kasperczyk et al.33 2016 | 1 | 0 | 1 | 2 |

**Discussion**

This systematic review and meta-analysis analyzed the effect of orally or intravenously administration of NAC on circulating inflammatory markers and Hcy levels in subjects with different diseases. Our findings demonstrated that NAC significantly decreased circulating Hcy levels, but did not affect CRP, IL-6, and TNF-α levels.

**Effects of NAC administration on inflammation markers**

There are a plethora of studies analyzing the beneficial impacts of NAC on CRP, IL-6, and TNF-α but their results are controversial. In a placebo-controlled randomized trial from Panizzuti et al.,24 treatment with 2000 mg/day of adjunctive NAC in patients with bipolar depression during 8 weeks and 32 weeks did not significantly change TNF-α, CRP and IL-6 levels. In another study, intake of 600 mg twice daily of NAC significantly reduced TNF-α and IL-6 levels during 1 month, but in the same study, a significant difference was not observed in markers of TNF-α and IL-6 levels during 12 months.25 Martin et al.26 showed that the administration of NAC with a dose of 600 mg, twice a day, during 6 months in hypertensive patients with type 2 diabetes mellitus resulted in a significant reduction of CRP levels. Guijarro et al.27 found that circulating IL-6 levels did not change significantly, with respect to baseline values, after treatment of ulcerative colitis patients with 0.8 g/d NAC in a randomized, placebo-controlled pilot study. Hasebe et al.28, in their study on patients with unipolar depression, showed that NAC supplementation with a dose of 2000 mg/day during 12-week detracted blood CRP, IL-6 values as compared to the placebo. A similar finding was seen in the study performed by Bashardoust et al.29, in which oral administration of 1200 mg daily of NAC supplementation during 1 month to patients undergoing hemodialysis showed a significant reduction in CRP levels. In the study of Abasi Larki et al.30, intake of 600 mg NAC every 12 hours for eight weeks significantly not change the IL-6 levels in the intervention group as compared to the control group. Increased inflammatory biomarkers and metabolic profiles increase the risk of CVD and diabetes.34-37 Suppression of inflammation markers production by NAC could be caused by inhibition of the pro-inflammatory transcription factor activators protein-1 (AP-1) and NF-κB.38 Induction of NF-κB and AP-1 in response to oxidative stress clarify a fundamental role of NAC in the modulation of inflammation-related genes due to the action mechanism of NAC as free radical-scavenger. However, these discrepancies in the valence of NAC between studies might be to some extent too because of variation in dosage of NAC, the longitude of treatment, baseline levels of NAC and inflammation markers, and also differences in the type of the disease.

**Effects of NAC administration on Hcy levels**

Hyperhomocysteinemia induces a large production of ROS in vascular cells and macrophages. These changes increase expression of several cytokines such as TNF-α, IL-1β and IL-6, monocyte chemoattractant protein-1, and intracellular adhesion molecule-1 due to activation of nuclear NF-κB and P2X7 pathways.39,40 This can contribute to development of diseases such as stroke, aortic aneurysm, myocardial infarction, Alzheimer's disease and epilepsy. Therefore, normalization of Hcy concentrations in different conditions can be a therapeutic target especially for patients with hyperhomocysteinemia. NAC is a thiol-containing compound broadly applied for therapy of acetaminophen poisoning41 and chronic obstructive pulmonary disease42 without drastic side effects.43 On the other hand, many other studies supported the idea that NAC administration orally or intravenously can acutely and dramatically decrease Hcy levels.21-23 Kasperczyk et al.44 showed that chronic oral treatment with NAC decreased Hcy levels and oxidative stress in a dose-dependent manner in lead-exposed workers. Similar with this study, NAC reduced Hcy levels in hemodialysis patients,44-46 kidney transplant recipients,47 patients with coronary artery disease,48 and patients undergoing cardiac angiography.49 These effects of NAC can be explained by removing of Hcy from protein binding sites, especially from circulating albumin. This could cause formation of disulfide forms which have a higher liver and kidney clearance that could facilitate their removal from plasma.50-52 On the other hand, given the knowledge that the administration of NAC can also increase antioxidant capacity. Our meta-analysis study’s results give prominence that NAC as an adjunctive approach along with other drugs can help to reduce homocysteine as an atherogenic agent.

It is important to note that first, most of the studies...
investigated on the property of NAC have been conducted on a small scale and require large-scale studies for a more definitive conclusion. Second, the number of studies per effect size is low and further studies are needed to obtain a more convincing conclusion. Third, duration of intervention is relatively short and may not be sufficient to obtain beneficial effects. Fourth, heterogeneity of results is generally high for most autosomes, which may affect the efficacy of results. Due to the low number of studies, a sensitivity analysis for publication bias was not conducted.

Conclusion
NAC has antioxidant properties and may diminishes inflammation. Meta-analysis of outcomes in our study indicated that NAC administration in different types of patients significantly lowered serum levels of Hcy, but did not affect inflammatory parameters including CRP, TNF-α and IL-6 levels.

Conflict of Interests
The authors declare that they have no conflict of interest.

References
1. Ziment I. Acetylcysteine: A drug that is much more than a mucokinetic. Biomed Pharmacother. 1988;42(8):513-9.
2. Kelly GS. Clinical applications of N-acetylcysteine. Altern Med Rev. 1998;3(2):114-27.
3. Dekhuijzen PN. Antioxidant properties of N-acetylcysteine: Their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J. 2004;23(4):629-36. doi:10.1183/09031936.04.0016804
4. Dröge W, Holm E. Role of cysteine and glutathione in hiv infection and other diseases associated with muscle wasting and immunological dysfunction. FASEB J. 1997;11(13):1077-89. doi:10.1096/fasebj.11.13.367343
5. Banner JrW, Koch M, Capin DM, Hopf SB, Chang S, Tong TG. Experimental chelation therapy in chromium, lead, and boron intoxication with n-acetylcysteine and other compounds. Toxicol Appl Pharmacol. 1986;83(1):142-7. doi:10.1016/0041-008x(86)90331-5
6. Prescott LF, Ballantyne A, Proudfoot AT, Park J, Adriaenssens P. Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. The Lancet. 1997;310(8035):432-4. doi:10.1016/S0140-6736(77)90312-2
7. Walters MT, Rubin CE, Keightley SJ, Ward CD, Cawley MJ. A double-blind, cross-over, study of oral n-acetylcysteine in sjögren's syndrome. Scand J Rheumatol Suppl. 1986;61:253-8.
8. De Flora S, Grassi C, Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term n-acetylcysteine treatment. Eur Respir J. 1997;10(7):1535-41. doi:10.1183/09031936.97.10071535
9. Moura FA, de Andrade KQ, Dos Santos JCF, Araújo ORP, Goulart MOE. Antioxidant therapy for treatment of inflammatory bowel disease: Does it work? Redox Biol. 2015;6:617-39. doi:10.1016/j.redox.2015.10.006
10. Li J, Zhang S, Wu Y, Guo W, Zhang Y, Zhai W. Protective effects of N-acetylcysteine on the liver of brain-dead Ba-Ma mini pig. Transplant Proc. 2010;42(1):195-99. doi:10.1016/j.transproceed.2009.12.039
11. Zhang Q, Ju Y, Ma Y, Wang T. N-acetylcysteine improves oxidative stress and inflammatory response in patients with community acquired pneumonia: A randomized controlled trial. Medicine (Baltimore). 2018;97(45):e13087. doi:10.1097/MD.0000000000013087
12. Gavish D, Breslow JL. Lipoprotein(a) reduction by N-acetylcysteine. Lancet. 1991;337(8735):203-4. doi:10.1016/0140-6736(91)92161-T
13. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of n-acetylcysteine: Its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med. 1989;6(6):593-7. doi:10.1016/0891-5849(89)90066-X
14. Rushworth GF, Megson IL. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacol Ther. 2014;141(2):150-9. doi:10.1016/j.pharmthera.2013.09.006
15. Kim H, Seo JY, Roh KH, Lim JW, Kim KH. Suppression of NF-kappaB activation and cytokine production by N-acetylcysteine in pancreatic acinar cells. Free Radic Biol Med. 2000;29(7):674-83. doi:10.1016/s0891-5849(00)00368-3
16. Pajonk F, Riess K, Sommer A, McBride WH. N-acetyl-L-cysteine inhibits 26S proteasome function: implications for effects on NF-kappaB activation. Free Radic Biol Med. 2002;32(6):536-43. doi:10.1016/s0891-5849(02)00743-8
17. Zafarullah M, Li WQ, Sylvester J, Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci. 2003;60(1):6-20. doi:10.1007/s000180300001
18. Selhub J. Homocysteine metabolism. Annu Rev Nutr. 1999;19:217-246. doi:10.1146/annurev.nutr.19.1.217
19. Bostom AG, Shemin D, Lapanke KL, et al. High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int. 1996;49(1):147-152. doi:10.1038/ki.1996.19
20. Yango A, Shemin D, Hsu N, Jacques PF, Dworkin L, Selhub J, et al. L-folinic acid versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Kidney Int. 2001;59(1):324-7. doi:10.1046/j.1523-1755.2001.00507.x
21. Ventura P, Panini R, Pasini MC, Scarpetta G, Salvioli G. N-acetyl-cysteine reduces homocysteine plasma levels after single intravenous administration by increasing thios urinary excretion. Pharmacol Res. 1999;40(4):345-50. doi:10.1016/S0041-008x(99)000519
22. Hultberg B, Andersson A, Masson P, Larson M, Tünek A. Plasma homocysteine and thiol compound fractions after oral administration of N-acetylcysteine. Scand J Clin Lab Invest. 1994;54(6):417-22. doi:10.3109/00365519409085646
23. Wiklund O, Fager G, Andersson A, Lundstam U, Masson P, Hultberg B. N-acetylcysteine treatment lowers plasma homocysteine but not serum
lipoprotein(a) levels. Atherosclerosis. 1996;119(1):99-106. doi:10.1002/1096-9150(95)05065-1
24. Panizzutti B, Bortolasci C, Hasebe K, Kidnapillai S, Gray L, Walder K, et al. Mediator effects of parameters of inflammation and neurogenesis from a N-acetylcysteine clinical-trial for bipolar depression. Acta Neuropsychiatr. 2018;30(6):334-41. doi:10.1017/neu.2018.13
25. Vural A, Koçyiğit İ, Şan F, Eroğlu E, Ketenç I, Ünal A, et al. Long-Term Protective Effect of N-Acetylcysteine against Amikacin-Induced Ototoxicity in End-Stage Renal Disease: A Randomized Trial. Perit Dial Int. 2018;38(1):57-62. doi:10.3747/pdi.2017.00133
26. Martina V, Masha A, Gigliardi VR, Brocato L, Manzano E, Berchio A, et al. Long-term N-acetylcysteine and L-arginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with type 2 diabetes. Diabetes Care. 2008;31(5):940-44. doi:10.2337/dc07-2251
27. Guijarro LG, Mate J, Gisbert JL, Martin-Jimenez I, Arriaza E, et al. N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: randomized, placebo-controlled pilot study. World J Gastroenterol. 2008;14(18):2851-57. doi:10.3748/wjg.v14.i18.2851
28. Hasebe K, Gray L, Bortolasci C, Panizzutti B, Mohebbi M, Kidnapillai S, et al. Adjunctive N-acetylcysteine in depression: exploration of interleukin-6, C-reactive protein and brain-derived neurotrophic factor. Acta Neuropsychiatr. 2017;29(6):337-46. doi:10.1017/neu.2017.12
29. Bashardoust B, Alaei R, Mohammadi Kebar S, Hasani S, Habibzadeh A. The effect of oral N-acetylcysteine on serum high sensitive CRP and plasma hemoglobin levels in end-stage renal disease patients under routine hemodialysis; a randomized placebo-controlled clinical trial. J Nephropathol. 2018;7(4):268-72. doi:10.15171/jnp.2018.53
30. Abasi Larki R, Panahi A, Manzouri L, Sedaghatalab M. Effect of n-acetylcysteine on inflammatory and biochemical markers of hemodialysis patients: A randomized controlled trial. Acta Med Iran. 2019;57(1):57-62. doi:10.18502/acta.v57i1.1754
31. Friedman AN, Bostom AG, Laliberty P, Selhub J, Friedman AN, Bostom AG, Laliberty P, Selhub J, Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med. 1981;319(24):1557-62. doi:10.1055/s-0035-1569276
32. Samimi M, Jamilian M, Afshar Ebrahimi F, Rahimi M, Tajbakhsh B, Asemi Z. Oral carnitine supplementation reduces body weight and insulin resistance in women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial. Clinical Endocrinology. 2016;84(6):851-7. doi:10.1111/cen.13003
33. Van Zant RF, Bergamin LS, Morrone FB, Coutinho-Silva R, de Souza Wyse AT, Battastini AMO. Pathological concentrations of homocysteine increases il-1β production in macrophages in a p2x7, nf-κb, and erk-dependent manner. Purinergic Signal. 2015;11(4):463-70. doi:10.1007/s11011-015-9464-5
34. Prescott LF. Treatment of severe acetaminophen poisoning with intravenous acetylcysteine. Arch Intern Med. 1981;141(3 Spec No):386-389. doi:10.1001/arch.hi.141.3.386
35. Borgenström I, Kägedal B, Paulsen O. Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol. 1986;31(2):217-22. doi:10.1007/BF00606662
36. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med. 1988;319(24):1557-62. doi:10.1056/N EJM198812153192401
37. Persson AF, Violette F, Lanza D, Sepe I, Bellinghieri G, Savica V, et al. Therapy of hyperhomocysteinemia in hemodialysis patients: effects of folates and N-acetylcysteine. J Ren Nutr. 2012;22(5):507-14.e1. doi:10.1053/j.jrn.2011.10.007
38. Scholze A, Rinder C, Beige J, Riezler R, Zidek W, Tepel M. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage
46. Thaha M, Yogiantoro M, Tomino Y. Intravenous N-acetylcysteine during haemodialysis reduces the plasma concentration of homocysteine in patients with end-stage renal disease. Clin Drug Investig. 2006;26(4):195-202. doi:10.2165/00044011-200626040-00003

47. Rymarz A, Durlik M, Rydzewski A. Intravenous administration of N-acetylcysteine reduces plasma total homocysteine levels in renal transplant recipients. Ann Transplant. 2009;14(4):5-9.

48. Yilmaz H, Sahin S, Sayar N, Tangurek B, Yilmaz M, Nurkalem Z, et al. Effects of folic acid and N-acetylcysteine on plasma homocysteine levels and endothelial function in patients with coronary artery disease. Acta Cardiol. 2007;62(6):579-85. doi:10.2143/AC.62.6.2024017

49. Wang JH, Subeq YM, Tsai WC, Lee RP, Hsu BG. Intravenous N-acetylcysteine with saline hydration improves renal function and ameliorates plasma total homocysteine in patients undergoing cardiac angiography. Ren Fail. 2008;30(5):527-33. doi:10.1080/08860220802064754

50. Raijmakers MT, Schilders GW, Roes EM, van Tits LJ, Hak-Lemmers HL, Steegers EA, Peters WH. N-Acetylcysteine improves the disturbed thiol redox balance after methionine loading. Clin Sci (Lond). 2003 Aug;105(2):173-80. doi:10.1042/CS20030052